Arrowhead Pharmaceuticals (ARWR) said Monday that topline results of the clinical study of its investigational RNA interference therapeutic ARO-C3 showed an 89% mean reduction in complement component 3, supporting it as a potential therapy for various complement-mediated diseases.
The second part of the phase 1/2 clinical study also showed reductions of 85% in AH50 and 100% in Wieslab AP, which are both markers of alternative pathway complement activity, in patients with IgA nephropathy, the company said.
Arrowhead also reported that the therapy was generally well tolerated by the patients, with no serious or severe treatment adverse events.
The study was designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of adult healthy volunteers and adult patients with complement-mediated renal disease.
The company said it plans to present additional results at an upcoming medical meeting later this year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。